Repositioning Candidate Details
| Candidate ID: | R0617 |
| Source ID: | DB04817 |
| Source Type: | approved; investigational; withdrawn |
| Compound Type: | small molecule |
| Compound Name: | Metamizole |
| Synonyms: | -- |
| Molecular Formula: | C13H17N3O4S |
| SMILES: | CN(CS(O)(=O)=O)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1 |
| Structure: |
|
| DrugBank Description: | Metamizole, formerly marketed as Dimethone tablets and injection, Protemp oral liquid, and other drug products, was associated with potentially fatal agranulocytosis. Approvals of the NDA's for dipyrone drug products were withdrawn on June 27, 1977 (see the Federal Register of June 17, 1977 (42 FR 30893)). Withdrawn from the Canadian market in 1963. |
| CAS Number: | 50567-35-6 |
| Molecular Weight: | 311.36 |
| DrugBank Indication: | Used in the past as a powerful painkiller and fever reducer. |
| DrugBank Pharmacology: | Dipyrone is a non-steroidal anti-inflammatory drug (NSAID), commonly used in the past as a powerful painkiller and fever reducer. |
| DrugBank MoA: | -- |
| Targets: | Prostaglandin G/H synthase 1 |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|